Should Opportunistic Bilateral Salpingectomy (OBS) for Prevention of Ovarian Cancer Be Incorporated Into Routine Care or Offered in the Context of a Clinical Trial?

Affiliation

• ¹ Department of Gynaecological Oncology, St. Bartholomew's Hospital Department of Women's Cancer, EGA Institute for Women's Health, University College London Barts Cancer Institute, Charterhouse Square London, UK r.manchanda@ucl.ac.uk Department of Obstetrics and Gynaecology, Northampton General Hospital, Northampton Department of Gynaecology, University College London Hospital, London Department of Women's Cancer, EGA Institute for Women's Health, University College London, London, United Kingdom Department of Gynaecological Oncology, Addenbrookes Hospital, Cambridge, United Kingdom Department of Gynaecological Oncology, St. Bartholomew's Hospital, London, United Kingdom Department of Women's Cancer, EGA Institute for Women's Health, University College London, London, United Kingdom Department of Obstetrics and Gynaecology, Northampton General Hospital, Northampton Department of Women's Cancer, EGA Institute for Women's Health, University College London.